Exposure of primary CLL cells to lenalidomide in vitro leads to the induction of costimulatory molecules like CD80, CD86, and FASL on the tumor cells [43], restoring immunological synapse formation and improving autologous tumor cell recognition by T cells [44, 45] (Figure 2). This evidence concerns the gene CD86 and neoplasm.